Project Mosaic is developing genetically-representative sporadic ALS disease models using induced pluripotent stem cells (iPSCs) to enhance the accuracy of drug development. This initiative addresses the high failure rates in ALS clinical trials by providing a standardized platform for targeted therapies, akin to cancer biopsies.
Funding
Funding not disclosed
Founders
Product
Problem
Drug development for sporadic Amyotrophic Lateral Sclerosis (ALS) faces high failure rates due to the disease's heterogeneity and the limitations of current preclinical models. Existing models often rely on genetic mutations found in a small subset of patients, failing to represent the diverse genetic and biological profiles of the majority of individuals with sporadic ALS. This lack of representative models hinders the development of effective, targeted therapies for this complex disease.
Solution
Project Mosaic is a collaborative research initiative focused on creating genetically-representative sporadic ALS disease models using induced pluripotent stem cells (iPSCs). By replicating and validating iPSC-based modeling methods, Project Mosaic aims to provide a standardized platform that captures the biological mosaicism of sporadic ALS. These models, derived from patient tissues, exhibit key features of the disease, such as TDP-43 dysfunction, and demonstrate heterogeneous drug responses, allowing for the classification of patient subgroups. The initiative seeks to accelerate drug development by enabling researchers and drug makers to account for the biological diversity of ALS before human trials, ultimately paving the way for precision medicine approaches.
Target Audience
The primary audience includes researchers, drug developers, and Contract Research Organizations (CROs) involved in ALS drug discovery, seeking more accurate and representative preclinical models to improve clinical trial success rates.
Features
- Utilizes iPSC-based models to represent the genetic diversity of sporadic ALS.
- Focuses on replicating and validating models that exhibit TDP-43 pathology.
- Aims to establish a catalog of well-characterized cell lines for the research community.
- Facilitates the identification of patient subgroups based on drug response.
- Provides a platform for high-throughput drug screening using patient-derived cell lines.
- Supports the development of targeted therapies tailored to specific ALS subtypes.